Clinical Myopia Control for Optometrists: Axial Length, MiSight, Atropine, Ortho-K, Treatment Failure, and Combination Therapy
Myopia management has moved beyond simply prescribing stronger glasses every year.
For the optometrist treating a progressing myopic child, the more important clinical question is:
How quickly is the eye growing, and is our treatment slowing that growth enough?
Cycloplegic refraction remains important, but axial length has increasingly become one of the most useful objective measurements for monitoring pediatric myopia. Modern management combines refractive change, axial elongation, age, family history, treatment adherence, visual behavior, and the response to previous therapy.
The goal is not necessarily to stop all ocular growth. Children are still growing, and some axial elongation is physiologic. Instead, treatment attempts to shift the child from a myopic growth trajectory toward a slower, age-appropriate ocular growth trajectory.
This article provides a practical framework for doing that in clinical practice.
Why Axial Length Matters in Myopia Management
Axial length measures the anterior-to-posterior length of the eye, generally from the cornea to the retinal pigment epithelium.
In most childhood myopia, increasing refractive error is driven primarily by excessive axial elongation.
That makes axial length particularly valuable because it provides an objective structural measurement that is largely independent of accommodation, patient responses during refraction, and examiner technique.
The International Myopia Institute notes that approximately 0.1 mm of axial growth per year may occur as part of normal ocular growth, whereas approximately 0.2–0.3 mm per year is commonly associated with progressive myopia, although considerable individual variation exists.
Axial length should therefore be interpreted as a trajectory, not simply as an isolated number.
A child with an axial length of 24.5 mm is not automatically a treatment failure, just as a child measuring 23.5 mm is not automatically low risk.
What matters clinically is:
age
baseline axial length
change over time
cycloplegic spherical equivalent
age of myopia onset
parental myopia
previous progression rate
current treatment
treatment adherence
Serial measurements are considerably more informative than a single measurement.
What Is Normal Axial Growth Versus Myopic Axial Growth?
One of the most useful concepts in myopia management is distinguishing physiologic ocular growth from excessive myopic elongation.
A practical framework is:
Axial Length Change | General Clinical Interpretation |
~0.00–0.10 mm/year | Excellent control in many older children |
~0.10–0.20 mm/year | May represent physiologic growth or mild residual progression, particularly in younger children |
~0.20–0.30 mm/year | Increasing concern for active myopic progression |
>0.30 mm/year | Rapid progression in most school-aged children |
These are clinical guideposts rather than absolute diagnostic thresholds. Age is critical. A 7-year-old may demonstrate more physiologic axial growth than a 14-year-old.
The IMI similarly cautions against assuming that one axial-growth threshold applies equally to every child.
A rough clinical relationship sometimes used is that approximately 0.1 mm of axial elongation may correspond to roughly 0.25 D of myopic refractive change, but the relationship is not constant because corneal power, crystalline lens changes, anterior chamber depth, and other biometric factors also influence refraction.
For this reason, it is usually better to document both:
Cycloplegic spherical equivalent progression and Axial length progression
rather than attempting to convert one directly into the other.
Expected Annual Myopia Progression
Untreated childhood myopia frequently progresses approximately 0.50 D or more per year, with younger children generally progressing faster than older adolescents.
Axial elongation tends to follow the same pattern: growth is usually faster near and shortly after myopia onset and gradually decreases with age.
A practical clinical interpretation might look like this:
Younger child with recent-onset myopia
A 7- to 9-year-old demonstrating:
−0.75 D/year of refractive progression
+0.25 to +0.35 mm/year axial elongation
should generally be considered an active progressor.
Older child under successful treatment
A 12- to 14-year-old demonstrating:
−0.00 to −0.25 D/year
approximately +0.05 to +0.10 mm/year
may be demonstrating very good treatment control.
Younger treated child
A 7-year-old growing +0.15 mm/year while receiving therapy should not automatically be labeled a failure.
Some ocular growth remains expected at that age.
This is why age-adjusted interpretation is superior to a rigid axial-length cutoff.
Establish a Baseline Before Starting Treatment
Whenever possible, obtain a thorough baseline before initiating myopia-control therapy.
A useful baseline examination includes:
unaided visual acuity
best-corrected visual acuity
cycloplegic refraction
manifest refraction when appropriate
binocular vision assessment
accommodative assessment when indicated
anterior segment examination
dilated fundus examination
axial length
keratometry
corneal topography when considering orthokeratology
previous spectacle prescriptions
family history of myopia
age of onset
outdoor exposure
near-work habits
current correction
previous myopia-control treatment
If previous prescriptions are available, calculate the historical rate of progression.
For example:
Previous year: −1.50 D
Current cycloplegic SER: −2.25 D
Approximate progression: −0.75 D/year
If axial length was previously 24.10 mm and is now 24.39 mm:
Axial elongation = +0.29 mm/year
That patient has considerably more useful baseline information than a patient classified simply as “−2.25 myope.”
Axial Length Should Become a Trend Line
Ideally, axial length should be measured with the same instrument under similar conditions at each visit.
Rather than recording:
AL OD 24.43 mmAL OS 24.39 mm
consider documenting:
OD: +0.09 mm over 6 months
OS: +0.08 mm over 6 months
and then annualizing the rate when clinically appropriate.
This immediately tells the clinician whether treatment appears to be controlling ocular growth.
However, be careful when annualizing very short intervals. A three-month change multiplied by four may exaggerate measurement noise or seasonal differences in ocular growth.
For most practices, six-month axial-length intervals provide a useful balance between early treatment assessment and meaningful change.
MiSight 1 Day: Clinical Fitting Protocol
MiSight 1 day is a daily disposable, dual-focus soft contact lens specifically indicated in the United States for slowing myopia progression in children who are 8–12 years old at treatment initiation, have a spherical equivalent refraction from −0.75 D to −4.00 D, and have ≤0.75 D of astigmatism.
Unlike orthokeratology, corneal topography is not routinely necessary to fit MiSight.
A standard contact-lens evaluation including keratometry, slit-lamp examination, tear-film assessment, and evaluation of lens position and movement is generally sufficient unless another corneal indication warrants topography.
Step 1: Obtain an accurate refraction
Begin with an accurate distance prescription.
Cycloplegic refraction is particularly important in younger children because accommodative tone can significantly influence the measured refractive error.
Avoid intentional undercorrection.
The goal is to provide clear distance vision while delivering the treatment optics incorporated into the MiSight design.
Step 2: Select the Initial Lens Power
Select the spherical lens power necessary to provide the appropriate distance correction.
After insertion:
allow the lens to settle
evaluate distance acuity
assess centration
evaluate movement
assess comfort
perform spherical over-refraction when necessary
Do not attempt to eliminate the therapeutic optics through excessive minus over-refraction.
Persistent reduced acuity should prompt consideration of:
uncorrected astigmatism
inaccurate refraction
accommodative fluctuation
poor lens centration
ocular surface problems
amblyopia
another ocular cause of decreased acuity
Step 3: Evaluate the Lens Like a Daily Disposable Soft Lens
MiSight fitting is considerably less topography-dependent than orthokeratology.
Evaluate:
complete corneal coverage
reasonable centration
appropriate movement
acceptable comfort
satisfactory binocular distance acuity
The lens should not demonstrate significant decentration or excessive movement.
Step 4: Train the Child and Parent
Insertion and removal training is a major part of successful pediatric contact-lens management.
Both the child and parent should understand:
hand washing and drying
insertion
removal
daily disposal
no sleeping in the lenses
no reuse
appropriate backup glasses
signs of contact-lens complications
Water exposure should also be discussed because contact lenses should not be exposed to tap water, pools, lakes, or other nonsterile water sources.
Step 5: Prescribe Adequate Wearing Time
The MiSight clinical study used substantial daily lens wear.
FDA labeling recommends at least 10 hours per day for at least 6 days per week based on the clinical study.
This becomes important when evaluating apparent treatment failure.
Before changing treatment, ask:
Is the child actually wearing the treatment?
A patient wearing MiSight three afternoons per week is not receiving the same exposure as the population from which efficacy data were derived.
What Results Should We Expect From MiSight?
The pivotal MiSight clinical program demonstrated a meaningful reduction in both refractive progression and axial elongation compared with conventional single-vision contact lenses. CooperVision reports approximately 59% less myopic refractive progression on average over the original three-year comparison period.
However, individual treatment response varies substantially.
Do not tell parents:
“This lens will stop the myopia.”
A more accurate discussion is:
“The purpose of treatment is to slow how quickly the prescription and the length of the eye increase.”
Some children will demonstrate very little progression.
Others will continue progressing despite excellent compliance.
The latter group requires reassessment rather than an assumption that all treatment has failed.
Low-Dose Atropine: How Should Optometrists Select a Concentration?
Atropine concentration selection remains one of the most debated areas of modern myopia management.
The key clinical point is that 0.01%, 0.025%, and 0.05% should not be assumed to have identical efficacy.
The LAMP trial demonstrated a concentration-dependent response among 0.01%, 0.025%, and 0.05% atropine, with 0.05% providing the greatest control of both spherical-equivalent progression and axial elongation among the concentrations studied.
Longer-term LAMP results have continued to support the efficacy of 0.05% atropine.
At the same time, atropine results have not been identical across populations.
A U.S. Pediatric Eye Disease Investigator Group randomized trial found that nightly 0.01% atropine did not significantly reduce myopia progression or axial elongation compared with placebo in U.S. children.
Other trials have shown benefits from 0.01%, illustrating why atropine therapy should not be reduced to a single universally effective concentration.
A Practical Atropine Concentration Strategy
There is no single universally accepted dosing algorithm, but a practical approach is to balance progression risk against treatment tolerance.
0.01% atropine
Potential advantages:
minimal pupillary dilation
minimal near blur
generally excellent tolerance
useful when higher concentrations are poorly tolerated
Limitations:
clinical efficacy appears less predictable
some studies show relatively weak axial-length control
U.S. randomized data have produced conflicting results
For a rapidly progressing young child, 0.01% monotherapy may therefore not always provide sufficient control.
0.025% atropine
This represents an intermediate option.
It may be reasonable when:
stronger treatment than 0.01% is desired
the child has experienced symptoms on 0.05%
progression risk is moderate rather than extreme
The LAMP data demonstrated greater efficacy than 0.01%, while generally producing fewer concentration-related visual effects than stronger atropine.
0.05% atropine
Among commonly studied low-dose concentrations, 0.05% currently has some of the strongest evidence for slowing axial elongation.
It may be particularly reasonable to consider in:
younger children
early-onset myopia
rapid progressors
children with two highly myopic parents
patients demonstrating substantial axial elongation
patients responding inadequately to weaker atropine concentrations
Higher low-dose concentrations can produce more:
photophobia
pupil dilation
near blur
accommodative reduction
A 2025 analysis of the MOSAIC trial also supported greater axial-growth control with 0.05% atropine, although transient near blur and photophobia occurred in some children.
The decision is therefore not simply:
Which concentration has the least side effects?
It is: Which concentration provides adequate biological effect while remaining tolerable for this child?
What Should Be Checked in a Child Taking Atropine?
At follow-up, assess:
distance visual acuity
near visual acuity
pupil size when clinically relevant
photophobia
accommodative symptoms
headaches
reading complaints
adherence
ocular surface
cycloplegic refraction at appropriate intervals
axial length
Ask specifically whether the child is actually receiving the drop every night.
“Most nights” can mean very different things to different families.
Orthokeratology: Axial Length Is More Important Than Refraction
Orthokeratology creates an important monitoring challenge.
After successful ortho-K treatment, the cornea has been intentionally reshaped. Daytime refractive error therefore no longer provides a straightforward measurement of the child's underlying myopic progression.
This is one reason axial length becomes especially important in orthokeratology patients.
The landmark ROMIO study demonstrated approximately 43% less axial elongation in children wearing orthokeratology lenses compared with single-vision spectacle controls.
Modern ortho-K management should therefore involve two separate questions:
Is the lens reshaping the cornea appropriately?
Is the eye itself still elongating excessively?
Corneal topography answers the first.
Axial length helps answer the second.
Baseline Topography Before Orthokeratology
Corneal topography should be obtained before fitting orthokeratology.
Evaluate:
simulated keratometry
corneal astigmatism
corneal eccentricity
HVID
corneal shape
asymmetry
irregular astigmatism
suspicious ectatic patterns
corneal scars
baseline apex position
A suspicious or irregular cornea should be investigated before proceeding.
The baseline map also becomes the comparison map for evaluating treatment-zone development.
What Should Good Ortho-K Topography Look Like?
After appropriate treatment, topography should generally demonstrate a relatively centered pattern consisting of:
Central flatteningrepresenting the treatment zone
surrounded by
Midperipheral steepeningassociated with the reverse-geometry effect.
On tangential or difference mapping, this often produces the classic bull's-eye appearance.
Evaluate:
treatment-zone centration
treatment-zone size
magnitude of central flattening
symmetry of the surrounding steepening
inferior or lateral decentration
residual refractive error
unaided visual acuity
Significant decentration can affect vision quality and may alter the distribution of peripheral defocus.
Treatment-zone characteristics may also influence myopia-control efficacy. Studies investigating smaller back optic zone diameters have demonstrated differences in treatment-zone size and axial elongation, although these specialized designs should not be interpreted as a universal fitting rule for every commercial ortho-K system.
Ortho-K Topography Follow-Up
A practical ortho-K schedule might include topography:
baseline
after the first night or early treatment period
approximately 1 week
approximately 1 month
approximately 3 months
every 6 months once stable
whenever acuity or lens performance changes
Early visits primarily determine whether the corneal reshaping pattern is safe and appropriate.
Later visits increasingly emphasize:
corneal health
lens integrity
treatment-zone stability
compliance
axial elongation
When Is Myopia Control Treatment Failing?
This is one of the most important questions in clinical myopia management.
There is no universally accepted single definition of treatment failure.
A child can continue growing while still receiving considerable benefit from treatment.
For example, suppose an untreated trajectory was likely to produce +0.35 mm/year of elongation, but treatment reduces that to +0.18 mm/year.
The eye is still growing.
But the therapy may still be providing clinically meaningful control.
Treatment failure should therefore not mean:
“Any progression occurred.”
Instead, ask:
“Is the rate of progression acceptable for this child's age and risk profile?”
Practical Red Flags for Inadequate Treatment Response
Clinical reassessment is reasonable when a treated patient demonstrates approximately:
≥0.20 mm of axial elongation per year
or
approximately ≥0.10 mm in six months with a persistent trend
particularly in an older child.
Likewise, continued refractive progression approaching or exceeding: −0.50 D/year should trigger closer evaluation.
These should be considered clinical warning thresholds rather than rigid definitions of failure. Research studies themselves frequently use approximately 0.20 mm/year to distinguish faster from slower axial elongation.
Younger children may require more nuanced interpretation because some physiologic ocular growth is still expected.
Before Declaring Treatment Failure, Check Compliance
The first response to unexpected progression should usually not be to immediately change modalities.
Verify treatment exposure.
MiSight
Ask:
hours per day?
days per week?
frequently lost lenses?
removing lenses after school?
wearing glasses instead?
Atropine
Ask:
nightly administration?
who instills the drops?
missed doses?
difficulty obtaining medication?
symptoms causing skipped doses?
Orthokeratology
Ask:
nights per week?
full-night wear?
lenses accidentally swapped?
lens age?
lens deposits?
cleaning technique?
poor centration?
inconsistent sleep schedule?
Apparent biological failure frequently turns out to be treatment-delivery failure.
Also Recheck the Diagnosis
Rapid progression despite therapy should prompt consideration of other factors.
Reassess:
cycloplegic refraction
accommodative spasm
keratoconus or corneal irregularity
changing corneal astigmatism
diabetes when clinically relevant
lens-induced refractive change
connective-tissue disorders in unusually high or progressive myopia
medication history
syndromic or pathologic myopia
retinal findings
A child progressing from −2.00 D to −5.00 D in a year deserves a different level of investigation than a typical −0.50 D annual progressor.
What Should We Do When Monotherapy Is Not Enough?
Once adherence, measurement reliability, ocular health, and treatment fit have been confirmed, clinicians have several options:
increase treatment intensity
change treatment modality
use combination therapy
The choice depends on which modality the patient is currently using.
Escalating Atropine
If a child demonstrates unacceptable progression on 0.01% atropine with excellent compliance, reasonable options include increasing to:
0.025%
or
0.05%
depending on age, progression rate, risk factors, and tolerance.
The concentration-response relationship demonstrated in LAMP provides a biological rationale for this approach.
Do not continue a low concentration indefinitely simply because the child tolerates it well if objective measurements suggest inadequate control.
Switching Optical Therapy
A patient progressing despite conventional correction or weak pharmacologic control may be considered for:
MiSight
another evidence-supported myopia-control soft lens
orthokeratology
myopia-control spectacle lenses
The decision should consider:
age
prescription
astigmatism
corneal shape
maturity
sports
lifestyle
parental preference
cost
ability to handle contact lenses
expected adherence
The “best” therapy is ineffective if the child will not use it.
Combination Therapy
Combination therapy is becoming increasingly important for children whose myopia progresses despite appropriate monotherapy.
However, combinations should be evidence-driven rather than based simply on the assumption that two treatments must always be better than one.
Orthokeratology Plus Atropine
The strongest combination-therapy evidence currently exists for orthokeratology plus low-dose atropine.
Randomized trials have demonstrated less axial elongation with ortho-K plus 0.01% atropine than with ortho-K alone. One study reported approximately 0.17 mm of axial elongation over two years with combined therapy versus 0.34 mm with orthokeratology alone.
Another randomized trial similarly found improved two-year axial control with combined atropine and orthokeratology compared with monotherapy.
More recent multicenter data continue to support an additive effect from 0.01% atropine plus orthokeratology.
This makes atropine augmentation particularly reasonable when:
the ortho-K treatment pattern is good
overnight compliance is excellent
daytime acuity is good
axial elongation nevertheless remains excessive
In this situation, abandoning a successful ortho-K fit may be unnecessary.
Adding pharmacologic therapy may be more logical.
MiSight or Multifocal Soft Lenses Plus Atropine
The evidence is less straightforward.
The Bifocal & Atropine in Myopia study found that adding 0.01% atropine to high-add multifocal soft contact lenses did not provide better myopia control than multifocal lenses alone.
Therefore, simply adding 0.01% atropine to every progressing soft-lens patient cannot be assumed to provide the same additive benefit seen with ortho-K.
For a child progressing on a myopia-control soft lens, first reconsider:
actual wearing time
refractive correction
lens centration
age
baseline risk
progression trajectory
If pharmacologic augmentation is considered, atropine concentration and the limited evidence for that particular combination should be discussed.
Do Not Judge Treatment by Percentage Reduction Alone
Clinical trials frequently describe treatments as reducing progression by a certain percentage.
Those numbers are useful for understanding population-level treatment efficacy but become problematic when applied to individual patients.
Imagine two children.
Child A
Expected untreated growth:
+0.40 mm/year
Treated growth:
+0.20 mm/year
Treatment effect:
approximately 50%
Child B
Expected untreated growth:
+0.20 mm/year
Treated growth:
+0.10 mm/year
Treatment effect:
also approximately 50%
Both show a similar proportional response, but their residual axial growth is very different.
For individual patient management, it is often more useful to examine:
absolute axial elongation
rather than relying solely on percentage efficacy reported in clinical studies.
Practical Myopia-Control Follow-Up Schedule
No single visit schedule applies to every modality, but the following represents a practical framework.
Initial Myopia-Control Evaluation
Obtain:
cycloplegic refraction
BCVA
binocular vision assessment
ocular health evaluation
axial length
keratometry
topography when indicated
family history
lifestyle history
previous progression rate
Then establish treatment.
MiSight Follow-Up
1–4 weeks after dispensing
Check:
VA
over-refraction
comfort
centration
movement
insertion/removal
wearing time
ocular surface
Approximately 3 months
Check:
visual acuity
lens performance
compliance
anterior segment
symptoms
Approximately 6 months
Include:
axial length
refraction as clinically appropriate
ocular health
compliance
Every 6 months thereafter
Trend axial length and refractive progression.
A cycloplegic examination annually is a practical approach for many children, with more frequent cycloplegia when the clinical findings require it.
Atropine Follow-Up
Approximately 4–8 weeks after initiation
Assess:
photophobia
near blur
pupil response
accommodative symptoms
adherence
Approximately every 3–6 months
Assess:
visual acuity
symptoms
adherence
axial length when due
Every 6 months
Axial length is particularly useful for evaluating pharmacologic response.
Annually
Repeat comprehensive cycloplegic examination unless more frequent testing is indicated.
Orthokeratology Follow-Up
A common practical schedule is:
after first overnight wear → 1 week → 1 month → 3 months → every 3–6 months
Early visits emphasize:
corneal health
unaided acuity
fluorescein pattern
lens position
topography
Long-term visits additionally emphasize:
axial elongation
lens condition
deposits
replacement
treatment-zone stability
compliance
A Simple Six-Month Decision Algorithm
At each six-month myopia-management assessment:
Step 1: Measure axial length
Compare with the previous measurement.
Step 2: Calculate change
For example:
24.30 mm → 24.37 mm
Change:
+0.07 mm over six months
Step 3: Consider age
For a young child, this may represent excellent control.
For an older teenager, you may expect even less growth.
Step 4: Compare refractive change
Does cycloplegic SER tell the same story?
Step 5: Confirm adherence
Was treatment delivered as prescribed?
Step 6: Evaluate the modality
For contact lenses:
fit
power
wear time
ocular health
For ortho-K:
topography
centration
treatment zone
lens condition
For atropine:
dose
compliance
tolerance
Step 7: Decide
Good control: continue.
Borderline control: observe more closely or reassess in 3–4 months.
Persistent excessive progression: intensify, switch, or combine treatment.
Example: Successful MiSight Treatment
An 8-year-old presents with:
Baseline cycloplegic SER: −2.00 D
Baseline axial length: 24.20 mm
Previous spectacle records show approximately −0.75 D of progression during the preceding year.
MiSight is initiated.
Six months later:
SER: −2.00 to −2.25 D
AL: 24.27 mm
Axial elongation: +0.07 mm
Annualized roughly: +0.14 mm/year
For an 8-year-old, this would generally represent a favorable response.
Continue treatment and monitor.
Example: Possible MiSight Treatment Failure
A 9-year-old begins MiSight at:
AL: 24.40 mm
Six months later:
AL: 24.55 mm
Change:
+0.15 mm in six months
Before declaring treatment failure:
Ask about wearing time.
The parent reports the child wears the lenses approximately four days per week and removes them after school.
The first intervention should likely be improving treatment exposure rather than immediately abandoning MiSight.
Recheck axial length after improving adherence.
Example: Ortho-K With Continued Axial Growth
A 10-year-old ortho-K patient has:
excellent unaided VA
centered bull's-eye topography
healthy corneas
nightly compliance
Axial length increases:
+0.23 mm over 12 months
The lens may be performing perfectly as a refractive device while myopic eye growth remains inadequately controlled.
Possible next steps include:
reassessing age-adjusted risk
confirming measurements
reviewing near/outdoor habits
considering atropine augmentation
This illustrates why excellent daytime vision does not necessarily mean excellent myopia control.
When Should Myopia-Control Treatment Be Stopped?
Treatment should not automatically stop when the child's prescription remains unchanged for one year.
Instead evaluate:
age
duration of stability
axial growth
pubertal development
previous progression
family history
current treatment
Many children continue progressing into their teenage years.
Atropine discontinuation also deserves particular attention because rebound can occur. Longer-term LAMP data suggest that many children may require retreatment when progression resumes after cessation.
A gradual taper may be considered for atropine in selected patients, particularly when higher concentrations have been used, although the ideal cessation protocol continues to evolve.
After discontinuing any myopia-control treatment, continue monitoring.
Stopping therapy does not mean stopping surveillance.
The Most Important Metric Is the Trajectory
The modern myopia-management visit should move away from:
“Your child's prescription changed another half diopter.”
and toward:
“During the last six months, the eye grew 0.06 mm. Based on the child's age and previous growth rate, the treatment appears to be controlling progression well.”
That conversation changes the clinical objective.
We are no longer simply reacting to refractive error.
We are managing ocular growth.
Clinical Pearls for Optometrists
1. Measure axial length whenever possible.Refraction measures the optical consequence of myopia. Axial length helps measure the structural progression.
2. Never interpret axial length without age.A younger child's eye normally grows faster than an older child's.
3. Track change rather than focusing on the absolute number.
4. Use cycloplegic refraction for meaningful longitudinal comparisons in children.
5. MiSight does not routinely require corneal topography.
6. MiSight treatment exposure matters.The FDA-labeled clinical-study recommendation is at least 10 hours per day, 6 days per week.
7. Orthokeratology requires topographic monitoring.
8. A perfect ortho-K bull's-eye does not prove that axial elongation is controlled.
9. Do not assume 0.01% atropine is equivalent to 0.05%.Atropine demonstrates concentration-dependent efficacy in several major trials.
10. Check compliance before changing treatment.
11. Approximately 0.20 mm/year of axial elongation while under treatment should get your attention, but it is not an absolute definition of failure.
12. Combination therapy is most strongly supported for atropine plus orthokeratology.
13. Adding 0.01% atropine to a multifocal soft contact lens has not consistently demonstrated additional benefit.
14. Monitor approximately every six months even when treatment appears successful.
15. The goal is not necessarily zero axial growth.The goal is to move the child toward an age-appropriate ocular growth trajectory and reduce cumulative lifetime myopia.
Final Clinical Perspective
Myopia control should be approached as long-term disease management rather than a one-time contact-lens fitting or prescription decision.
A useful clinical framework is:
Measure → Treat → Re-measure → Evaluate response → Adjust treatment
Axial length provides the objective biomarker.
Cycloplegic refraction provides the optical outcome.
MiSight and other myopia-control optics alter retinal defocus.
Orthokeratology reshapes the cornea while modifying the peripheral optical environment.
Atropine provides a pharmacologic approach to slowing ocular growth.
Combination therapy provides an additional option for selected children who continue progressing despite appropriate monotherapy.
Most importantly, no treatment should be placed on autopilot.
The child who begins therapy at age eight may require a different strategy at age ten, twelve, or fourteen.
The successful myopia-management practice therefore does not simply prescribe treatment.
It measures the biological response to treatment and modifies the plan accordingly.
References and Evidence Base
Clinical recommendations in this article are informed by the International Myopia Institute clinical management guidance, the MiSight FDA labeling and clinical program, the LAMP atropine trials, U.S. atropine randomized trials, BLINK/BAM investigations, and randomized orthokeratology and combination-therapy studies.
This article is intended for eye-care professionals and is educational in nature. Individual treatment decisions should incorporate current product labeling, patient-specific findings, contraindications, informed consent, and applicable standards of care.
Comments